First Hawaiian Bank Grows Position in GSK PLC Sponsored ADR $GSK

Key Points

• First Hawaiian Bank increased its stake in GSK PLC by 18.8% during the first quarter, bringing its holdings to 101,039 shares valued at approximately $3.9 million.
• Several other institutional investors have also significantly raised their positions in GSK, with HHM Wealth Advisors increasing its stake by 222.2% and Cary Street Partners by 525.9%.
• GSK reported Q2 earnings of $1.23 per share, beating estimates, with revenues of $10.64 billion, illustrating a year-over-year growth of 1.3%.

First Hawaiian Bank boosted its stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 18.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 101,039 shares of the pharmaceutical company's stock after acquiring an additional 15,987 shares during the period. First Hawaiian Bank's holdings in GSK were worth $3,914,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Kingsview Wealth Management LLC boosted its holdings in GSK by 1.8% in the first quarter. Kingsview Wealth Management LLC now owns 15,227 shares of the pharmaceutical company's stock valued at $590,000 after acquiring an additional 271 shares during the last quarter. Rehmann Capital Advisory Group boosted its holdings in GSK by 4.6% in the first quarter. Rehmann Capital Advisory Group now owns 6,407 shares of the pharmaceutical company's stock valued at $248,000 after acquiring an additional 279 shares during the last quarter. First PREMIER Bank boosted its holdings in GSK by 6.5% in the first quarter. First PREMIER Bank now owns 4,659 shares of the pharmaceutical company's stock valued at $181,000 after acquiring an additional 286 shares during the last quarter. Northwest Bank & Trust Co boosted its holdings in GSK by 1.3% in the fourth quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company's stock valued at $765,000 after acquiring an additional 289 shares during the last quarter. Finally, OneAscent Financial Services LLC boosted its holdings in GSK by 3.9% in the first quarter. OneAscent Financial Services LLC now owns 7,700 shares of the pharmaceutical company's stock valued at $297,000 after acquiring an additional 292 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

GSK Stock Down 1.6%

Shares of NYSE:GSK traded down $0.67 during trading on Friday, reaching $40.81. 4,741,956 shares of the stock were exchanged, compared to its average volume of 3,638,441. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. GSK PLC Sponsored ADR has a 1-year low of $31.72 and a 1-year high of $43.62. The stock has a fifty day moving average of $38.74 and a two-hundred day moving average of $38.47. The firm has a market cap of $83.12 billion, a price-to-earnings ratio of 18.89, a price-to-earnings-growth ratio of 2.04 and a beta of 0.53.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping analysts' consensus estimates of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The company had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. During the same period in the prior year, the firm earned $0.43 earnings per share. GSK's revenue for the quarter was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Research analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be given a dividend of $0.4206 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date of this dividend is Friday, August 15th. GSK's dividend payout ratio is presently 77.78%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on GSK. Wall Street Zen upgraded GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, September 5th. Berenberg Bank restated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Six equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Reduce" and a consensus target price of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.